与FRAX相比,德国DVO风险评分确定了更多需要治疗的患者。

IF 2.8 3区 医学 Q3 ENDOCRINOLOGY & METABOLISM
Endocrine Connections Pub Date : 2025-04-08 Print Date: 2025-05-01 DOI:10.1530/EC-25-0048
Anna Frank, Judith Charlotte Witzel, Christina Heppner, Annette Lamersdorf, Andreas Leha, Heide Siggelkow
{"title":"与FRAX相比,德国DVO风险评分确定了更多需要治疗的患者。","authors":"Anna Frank, Judith Charlotte Witzel, Christina Heppner, Annette Lamersdorf, Andreas Leha, Heide Siggelkow","doi":"10.1530/EC-25-0048","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Fracture risk determination is essential when recommending treatment in osteoporosis management. We calculated the risk probabilities of major osteoporotic and hip fractures using the DVO score established in German-speaking countries and the FRAX tool.</p><p><strong>Methods: </strong>We retrospectively analysed data from 555 female patients (mean age 64.2 ± 10.3 years) evaluated for osteoporosis. As suggested by DVO guidelines before 2023, we set the therapy threshold of >30% for vertebral and hip fractures. Major osteoporotic fracture (MOF) and hip fracture risk (HF) were calculated based on corresponding FRAX scores. We applied the internationally most common therapy threshold of ≥20% for MOF and ≥3% for HF and determined the 'DVO-equivalent risk levels' for FRAX-based assessment.</p><p><strong>Results: </strong>The DVO score identified 52.8% of women as having a 10-year risk of hip and vertebral fractures >30%. FRAX score for HF ≥ 3% without bone mineral density (BMD) identified the highest number of patients (56%). The proportion of female patients identified for treatment only by DVO score (14.6%) were more likely to present spinal fractures (38.3 vs 18.6%), whereas the 10.6% of patients only identified by FRAX including BMD presented more peripheral fractures (40.7 vs 29.6%). The thresholds for this 'DVO-equivalent risk level' for 'FRAX with BMD' would be ≥10% for MOF and ≥2.6% for HF.</p><p><strong>Conclusion: </strong>Given the differences in the DVO and FRAX scores, we highly recommend considering both scores when assessing individual women for treatment.</p>","PeriodicalId":11634,"journal":{"name":"Endocrine Connections","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12007879/pdf/","citationCount":"0","resultStr":"{\"title\":\"German DVO risk score identified more patients requiring treatment compared to FRAX.\",\"authors\":\"Anna Frank, Judith Charlotte Witzel, Christina Heppner, Annette Lamersdorf, Andreas Leha, Heide Siggelkow\",\"doi\":\"10.1530/EC-25-0048\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Fracture risk determination is essential when recommending treatment in osteoporosis management. We calculated the risk probabilities of major osteoporotic and hip fractures using the DVO score established in German-speaking countries and the FRAX tool.</p><p><strong>Methods: </strong>We retrospectively analysed data from 555 female patients (mean age 64.2 ± 10.3 years) evaluated for osteoporosis. As suggested by DVO guidelines before 2023, we set the therapy threshold of >30% for vertebral and hip fractures. Major osteoporotic fracture (MOF) and hip fracture risk (HF) were calculated based on corresponding FRAX scores. We applied the internationally most common therapy threshold of ≥20% for MOF and ≥3% for HF and determined the 'DVO-equivalent risk levels' for FRAX-based assessment.</p><p><strong>Results: </strong>The DVO score identified 52.8% of women as having a 10-year risk of hip and vertebral fractures >30%. FRAX score for HF ≥ 3% without bone mineral density (BMD) identified the highest number of patients (56%). The proportion of female patients identified for treatment only by DVO score (14.6%) were more likely to present spinal fractures (38.3 vs 18.6%), whereas the 10.6% of patients only identified by FRAX including BMD presented more peripheral fractures (40.7 vs 29.6%). The thresholds for this 'DVO-equivalent risk level' for 'FRAX with BMD' would be ≥10% for MOF and ≥2.6% for HF.</p><p><strong>Conclusion: </strong>Given the differences in the DVO and FRAX scores, we highly recommend considering both scores when assessing individual women for treatment.</p>\",\"PeriodicalId\":11634,\"journal\":{\"name\":\"Endocrine Connections\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-04-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12007879/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Endocrine Connections\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1530/EC-25-0048\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/1 0:00:00\",\"PubModel\":\"Print\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine Connections","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1530/EC-25-0048","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/1 0:00:00","PubModel":"Print","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

目的:骨折风险测定是推荐骨质疏松症治疗的必要条件。我们使用在德语国家建立的DVO评分和FRAX工具计算了主要骨质疏松症和髋部骨折的风险概率。方法:回顾性分析555例骨质疏松症女性患者(平均年龄64.2±10.3岁)的资料。根据2023年之前DVO指南的建议,我们将椎体和髋部骨折的治疗阈值设定为bbb30 %。根据相应的FRAX评分计算主要骨质疏松性骨折(MOF)和髋部骨折风险(HF)。我们采用了国际上最常见的治疗阈值,MOF≥20%,HF≥3%,并确定了基于frax评估的“dvo等效风险水平”。结果:DVO评分显示,52.8%的女性在10年内有髋部和椎体骨折的风险,其中30%为风险。HF≥3%无BMD时FRAX评分确定的患者数量最多(56%)。仅通过DVO评分确定治疗的女性患者比例(14.6%)更容易出现脊柱骨折(38.3%比18.6%),而仅通过FRAX包括BMD确定治疗的患者比例(10.6%)更容易出现外周骨折(40.7%比29.6%)。“FRAX合并BMD”的“dvo等效风险水平”阈值为MOF≥10%,HF≥2.6%。结论:考虑到DVO和FRAX评分的差异,我们强烈建议在评估女性个体治疗时考虑这两个评分。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

German DVO risk score identified more patients requiring treatment compared to FRAX.

German DVO risk score identified more patients requiring treatment compared to FRAX.

German DVO risk score identified more patients requiring treatment compared to FRAX.

German DVO risk score identified more patients requiring treatment compared to FRAX.

Purpose: Fracture risk determination is essential when recommending treatment in osteoporosis management. We calculated the risk probabilities of major osteoporotic and hip fractures using the DVO score established in German-speaking countries and the FRAX tool.

Methods: We retrospectively analysed data from 555 female patients (mean age 64.2 ± 10.3 years) evaluated for osteoporosis. As suggested by DVO guidelines before 2023, we set the therapy threshold of >30% for vertebral and hip fractures. Major osteoporotic fracture (MOF) and hip fracture risk (HF) were calculated based on corresponding FRAX scores. We applied the internationally most common therapy threshold of ≥20% for MOF and ≥3% for HF and determined the 'DVO-equivalent risk levels' for FRAX-based assessment.

Results: The DVO score identified 52.8% of women as having a 10-year risk of hip and vertebral fractures >30%. FRAX score for HF ≥ 3% without bone mineral density (BMD) identified the highest number of patients (56%). The proportion of female patients identified for treatment only by DVO score (14.6%) were more likely to present spinal fractures (38.3 vs 18.6%), whereas the 10.6% of patients only identified by FRAX including BMD presented more peripheral fractures (40.7 vs 29.6%). The thresholds for this 'DVO-equivalent risk level' for 'FRAX with BMD' would be ≥10% for MOF and ≥2.6% for HF.

Conclusion: Given the differences in the DVO and FRAX scores, we highly recommend considering both scores when assessing individual women for treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Endocrine Connections
Endocrine Connections Medicine-Internal Medicine
CiteScore
5.00
自引率
3.40%
发文量
361
审稿时长
6 weeks
期刊介绍: Endocrine Connections publishes original quality research and reviews in all areas of endocrinology, including papers that deal with non-classical tissues as source or targets of hormones and endocrine papers that have relevance to endocrine-related and intersecting disciplines and the wider biomedical community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信